Search Results 1221-1230 of 21668 for Inhibition
... inhibitors, or aspirin >100 mg/day within 2 weeks prior to Screen 2; TNF-alpha inhibitors including but not limited to infliximab (Remicade) or adalimumab ...
Diabetic subject on thiazolidinediones, insulin, GLP-1 based therapies (exenatide or sitagliptin), alpha-glucosidase inhibitors, glyburide or combination ...
Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon, kinase inhibitors or other targeted small molecules, and toxin ...
... inhibitor, applied either as monotherapy or in combination with other therapies as treatment for unresectable or metastatic cutaneous melanoma * Patients ...
Failed medication trials or contraindication to gabapentinoid medications (gabapentin, pregabalin) and/or serotonin/norepinephrine reuptake inhibitors ( ...
Stable (<10% change in dose) for 6 weeks prior to screening; Bruton's tyrosine kinase inhibitor dose must be stable (<10% change in dose) for 8 weeks prior ...
... inhibitor) and pembrolizumab (PD-1 inhibitor), in combination with chemotherapy. To receive immunotherapy at this time, the patient's cancer tissue must ...
... inhibitors. Any other ongoing investigational agents; History of allergic reactions attributed to compounds of similar chemical or biologic composition to ...
Nintedanib belongs to the group of drugs called tyrosine kinase inhibitors. This medicine is available only with your doctor's prescription. This product is ...
If taking inhibitors of P glycoprotein (P-gp), except for verapamil, dose must be stable for 7 days prior to screening; Provide written informed consent ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.